We have detected that you are using some form of ad-blocking or filtering.
Please consider white-listing Labnodes since 1) ad-blockers like uBlock break Labnodes functionality and 2) Labnodes does not serve ads.
We recently demonstrated that dual therapy combining AURKA and MDM2 antagonists is effective against melanoma in preclinical settings. Notably, besides inducing apoptosis, this regimen led to tumor senescence and stimulated the host's antitumor immune defenses. Treatments leveraging both cancer cell-intrinsic and extrinsic antitumor mechanisms can improve melanoma therapeutic outcomes.
This publication is referenced by other Labnodes entities:
© 2010-2021. All Rights Reserved to Vanderbilt University. Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Version 2.23
Released July 13, 2020